

# Daniel P Hart

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1957159/publications.pdf>

Version: 2024-02-01

33  
papers

1,442  
citations

516710

16  
h-index

454955

30  
g-index

35  
all docs

35  
docs citations

35  
times ranked

1937  
citing authors

#	ARTICLE	IF	CITATIONS
1	International consensus recommendations on the management of people with haemophilia B. Therapeutic Advances in Hematology, 2022, 13, 204062072210852.	2.5	13
2	New challenges for an expanding generation of older persons with haemophilia. The Journal of Haemophilia Practice, 2022, 9, 1-13.	0.4	0
3	Gene therapy of hemophilia: Hub centres should be haemophilia centres: A joint publication of EAHAD and EHC. Haemophilia, 2022, 28, .	2.1	10
4	Factor VIII/IX inhibitor testing practices in the United Kingdom: Results of a UKHCDO and UKNEQAS national survey. Haemophilia, 2021, 27, 490-499.	2.1	2
5	Optimizing language for effective communication of gene therapy concepts with hemophilia patients: a qualitative study. Orphanet Journal of Rare Diseases, 2021, 16, 189.	2.7	15
6	Haemophilia. Nature Reviews Disease Primers, 2021, 7, 45.	30.5	103
7	Immune tolerance induction in severe haemophilia A: A UKHCDO inhibitor and paediatric working party consensus update. Haemophilia, 2021, 27, 932-937.	2.1	16
8	Commentary on "Development of a novel fully functional coagulation factor VIII with reduced immunogenicity utilizing an in silico prediction and deimmunization approach" Will we ever be able to avoid inhibitor formation in hemophilia A?. Journal of Thrombosis and Haemostasis, 2021, 19, 2125-2126.	3.8	0
9	The factor VIII treatment history of non-severe hemophilia A "Response from original authors Abdi et al. Journal of Thrombosis and Haemostasis, 2021, 19, 2642-2644.	3.8	1
10	Delivery of AAV-based gene therapy through haemophilia centres "A need for re-evaluation of infrastructure and comprehensive care: A Joint publication of EAHAD and EHC. Haemophilia, 2021, 27, 967-973.	2.1	29
11	PERSEPT 3: A phase 3 clinical trial to evaluate the haemostatic efficacy of eptacog beta (recombinant) Tj ETQq1 1 0.784314 rgBT /Overl 2021, 27, 911-920.	2.1	5
12	Novel manifestations of immune dysregulation and granule defects in gray platelet syndrome. Blood, 2020, 136, 1956-1967.	1.4	34
13	FVIII Immunogenicity "Bioinformatic Approaches to Evaluate Inhibitor Risk in Non-severe Hemophilia A. Frontiers in Immunology, 2020, 11, 1498.	4.8	0
14	Letter in response to: Coagulation markers are independent predictors of increased oxygen requirements and thrombosis in COVID-19. Journal of Thrombosis and Haemostasis, 2020, 18, 3382-3384.	3.8	4
15	Lupus Anticoagulant and Abnormal Coagulation Tests in Patients with Covid-19. New England Journal of Medicine, 2020, 383, 288-290.	27.0	418
16	Von Willebrand factor. Clinical Medicine, 2020, 20, e279-e279.	1.9	2
17	Recombinant factor VIII products and inhibitor development in previously untreated patients with severe haemophilia A: Combined analysis of three studies. Haemophilia, 2019, 25, 398-407.	2.1	27
18	Re-personalization and stratification of hemophilia care in an evolving treatment landscape. Hematology, 2019, 24, 737-741.	1.5	6

#	ARTICLE	IF	CITATIONS
19	Perioperative laboratory monitoring in congenital haemophilia patients with inhibitors. <i>Blood Coagulation and Fibrinolysis</i> , 2019, 30, 309-323.	1.0	1
20	Treatment regimens and outcomes in severe and moderate haemophilia A in the UK: The THUNDER study. <i>Haemophilia</i> , 2019, 25, 205-212.	2.1	51
21	Factor VIII cross-matches to the human proteome reduce the predicted inhibitor risk in missense mutation hemophilia A. <i>Haematologica</i> , 2019, 104, 599-608.	3.5	6
22	Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: Rationale and general considerations. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2018, 2, 535-548.	2.3	50
23	Treatment burden, haemostatic strategies and real world inhibitor screening practice in non-severe haemophilia A. <i>British Journal of Haematology</i> , 2017, 176, 796-804.	2.5	21
24	Adherence to Prophylaxis in Adolescents and Young Adults with Severe Haemophilia: A Quantitative Study with Patients. <i>PLoS ONE</i> , 2017, 12, e0169880.	2.5	39
25	Inhibitors in nonsevere haemophilia A: outcome and eradication strategies. <i>Thrombosis and Haemostasis</i> , 2015, 114, 46-55.	3.4	33
26	Diagnostic accuracy study of a factor VIII ELISA for detection of factor VIII antibodies in congenital and acquired haemophilia A. <i>Thrombosis and Haemostasis</i> , 2015, 114, 804-811.	3.4	19
27	A large-scale computational study of inhibitor risk in non-severe haemophilia A. <i>British Journal of Haematology</i> , 2015, 168, 413-420.	2.5	19
28	Pre-analytical heat treatment and a FVIII ELISA improve Factor VIII antibody detection in acquired haemophilia A. <i>British Journal of Haematology</i> , 2014, 166, 953-956.	2.5	24
29	Factor VIII brand and the incidence of factor VIII inhibitors in previously untreated UK children with severe hemophilia A, 2000-2011. <i>Blood</i> , 2014, 124, 3389-3397.	1.4	110
30	Managing Acquired Haemophilia (A): Pan London Experience-Relating to the European Acquired Haemophilia (EACH2) Registry Data. <i>Blood</i> , 2014, 124, 1512-1512.	1.4	0
31	Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). <i>British Journal of Haematology</i> , 2013, 160, 153-170.	2.5	192
32	Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A. <i>Blood</i> , 2013, 122, 1954-1962.	1.4	188
33	A Two Centre Experience Of Use Of a Dual Virally Inactivated FVIII/VWF Product (Wilate®) In Patients With Von Willebrand Disease. <i>Blood</i> , 2013, 122, 1112-1112.	1.4	1